As glucose levels increased, sepsis-related mortality also increased: 0.9% in the euglycemic group, 3.5% in the mild hyperglycemia group, and 19.3% in the overt hyperglycemia group. Hyperglycemia is a ...

The highest risks were observed for bladder cancer, leukemia, nonmelanoma skin cancer, and kidney cancer. Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have a ...

Patients with AATD had a 1.6-fold higher risk of any type of middle ear surgery, even after adjusting for age, sex, COPD, and liver cirrhosis. Patients with alpha-1 antitrypsin deficiency (AATD) are ...

Already approved in the United States and United Kingdom under the brand name Ekterly®, sebetralstat is now awaiting a final decision from the European Commission, expected by early October 2025.

Four patients who had severe nephrotic syndrome unresponsive to tafamidis quickly responded to a change in siRNA therapy Patients with hereditary transthyretin amyloid polyneuropathy (ATTR-PN) ...

Findings from inverse variance weighting analysis showed that the presence of hypothyroidism might increase an individual’s risk for PAH (OR, 1.485; 95% CI, 1.051-2.100; P = .025). The presence of ...

Whole-genome resequencing used to assess ATP7B genotypes found a higher frequency of impaired finger tapping in patients carrying the p.P992L mutation. A variety of sociodemographic factors were found ...

Although patients without nerve blocks required more opioids at discharge, mean and maximum postoperative pain scores were comparable. General anesthesia alone was noninferior to regional nerve ...

Sphingomyelin (SM) appears to be a potentially valuable biomarker for the diagnosis, staging, and monitoring of demyelinating diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP) ...

Patients experienced a second tryptase peak approximately 100 days after hematopoietic cell transplantation, coinciding with the tapering of graft-versus-host disease prophylaxis. Hematopoietic cell ...

There are significant differences in terms of survival between non-anemic patients with MF, those with nontransfusion-dependent anemia, and those with transfusion-dependent anemia. A team of ...

The safety profile of the investigational regimen was manageable, with low-grade cytokine release syndrome and no treatment-related discontinuations. Epcoritamab, in combination with rituximab, ...